title: 31P-magnetic resonance spectra of ovarian cancer cells exposed to chemotherapy within a three-dimensional Matrigel construct.
abstract: We aimed to determine the metabolic profile and effects of chemotherapy             on ovarian cancer cell metabolism in a three-dimensional (3D) vs. a two-dimensional             (2D) construct using 31P-magnetic resonance spectroscopy (MRS). Three ovarian             cancer cell lines were embedded in a 3D perfused Matrigel construct or grown in             a 2D monolayer. Metabolic differences between the three cell lines were determined             using 31P-MRS both in the 3D and in the 2D constructs. Cells were incubated with             three different cytotoxic drugs at LC50 for 44 h and evaluated for metabolic changes             using 31P-MRS. While the 3D construct allowed MRS assessment of viable cells,             the 2D monolayer permitted evaluation of non-viable cell extracts. In both cells             embedded in Matrigel (CEM) and cells grown in monolayers (CGM) different cancer             cell lines showed characteristic metabolic fingerprints, which differed significantly             between CEM and CGM. In contrast to the cell monolayer, CEM allowed continuous             monitoring of the changes in 31P-MRS spectra over time following exposure to chemotherapy,             demonstrating a progressive decrease in specific phosphorylated metabolites. The             metabolic response of CEM and CGM to various antimitotic agents was significantly             different. We conclude that different ovarian cancer cell lines show characteristic             31P-MRS fingerprints and specific metabolic changes in response to cytotoxic drug             treatment. The perfused 3D Matrigel construct is superior to the 2D tissue monolayer             for 31P-MRS studies, because it simulates the in vivo conditions more closely             and facilitates MRS evaluation of viable cells as well as continuous monitoring             of metabolic changes in response to chemotherapy over time.
authors.affiliation: Department of Obstetrics and Gynecology, Carmel Medical Center, Technion University, Rappaport Faculty of Medicine, Haifa, Israel. yabramov@012.net.il
authors.forename: Yoram
authors.initials: Y
authors.lastname: Abramov
authors.forename: Shani
authors.initials: S
authors.lastname: Carmi
authors.forename: Jack S
authors.initials: JS
authors.lastname: Cohen
authors.forename: Shaoul O
authors.initials: SO
authors.lastname: Anteby
authors.forename: Israel
authors.initials: I
authors.lastname: Ringel
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D018920:Coculture Techniques; D003094:Collagen / Q000737:chemistry; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007797:Laminin / Q000737:chemistry; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D011509:Proteoglycans / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D007797:Laminin; D011509:Proteoglycans; C059485:matrigel; D003094:Collagen